| Literature DB >> 33385396 |
Chiara Pirazzini1, Tiago Azevedo2, Luca Baldelli3, Anna Bartoletti-Stella1, Giovanna Calandra-Buonaura4, Alessandra Dal Molin5, Giovanna Maria Dimitri2, Ivan Doykov6, Pilar Gómez-Garre7, Sara Hägg8, Jenny Hällqvist6, Claire Halsband9, Wendy Heywood10, Silvia Jesús7, Juulia Jylhävä8, Katarzyna Malgorzata Kwiatkowska11, Miguel A Labrador-Espinosa7, Cristina Licari12, Maria Giovanna Maturo13, Giacomo Mengozzi1, Gaia Meoni14, Maddalena Milazzo11, Maria Teresa Periñán-Tocino7, Francesco Ravaioli11, Claudia Sala15, Luisa Sambati4, Sebastian Schade16, Sebastian Schreglmann17, Simeon Spasov2, Leonardo Tenori18, Dylan Williams8, Luciano Xumerle5, Elisa Zago5, Kailash P Bhatia17, Sabina Capellari4, Pietro Cortelli4, Paolo Garagnani11, Henry Houlden19, Pietro Liò2, Claudio Luchinat20, Massimo Delledonne21, Kevin Mills10, Pablo Mir7, Brit Mollenhauer22, Christine Nardini23, Nancy L Pedersen8, Federica Provini4, Stephen Strom24, Claudia Trenkwalder25, Paola Turano20, Maria Giulia Bacalini26, Claudio Franceschi27.
Abstract
Advanced age is the major risk factor for idiopathic Parkinson's disease (PD), but to date the biological relationship between PD and ageing remains elusive. Here we describe the rationale and the design of the H2020 funded project "PROPAG-AGEING", whose aim is to characterize the contribution of the ageing process to PD development. We summarize current evidences that support the existence of a continuum between ageing and PD and justify the use of a Geroscience approach to study PD. We focus in particular on the role of inflammaging, the chronic, low-grade inflammation characteristic of elderly physiology, which can propagate and transmit both locally and systemically. We then describe PROPAG-AGEING design, which is based on the multi-omic characterization of peripheral samples from clinically characterized drug-naïve and advanced PD, PD discordant twins, healthy controls and "super-controls", i.e. centenarians, who never showed clinical signs of motor disability, and their offspring. Omic results are then validated in a large number of samples, including in vitro models of dopaminergic neurons and healthy siblings of PD patients, who are at higher risk of developing PD, with the final aim of identifying the molecular perturbations that can deviate the trajectories of healthy ageing towards PD development.Entities:
Keywords: Inflammaging; Neurodegeneration; Omics; Parkinson's disease
Year: 2020 PMID: 33385396 DOI: 10.1016/j.mad.2020.111426
Source DB: PubMed Journal: Mech Ageing Dev ISSN: 0047-6374 Impact factor: 5.432